Novartis announced new long-term data from the ALITHIOS open-label extension study showing that up to five years, patients treated earlier and continuously with Kesimpta® had fewer disability worsening events and low brain volume change versus those who started on teriflunomide and were later switched to Kesimpta.
Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, announced its business update and interim report for January to March 2023.
Hansa Biopharma interim report January-March 2023 Read More »
IRLAB Therapeutics AB, a company that discovers and develops new treatments for Parkinson’s disease, announced that the company’s annual report for 2022 will be published during the week commencing April 24.
IRLAB Announces New Date for Publication of the Annual Report Read More »
BioInvent International AB announces that a fourth complete response has been observed in the 100 mg dose expansion cohort in the IV arm of the Phase 1/2 trial of its lead drug candidate BI-1206, the novel anti-FcgRIIB antibody, in combination with rituximab in non-Hodgkin’s lymphoma.
Innovent Biologics, Inc., announced that the overall survival results of the Phase 2 study of pemigatinib in Chinese patients with advanced cholangiocarcinoma were presented at the American Association for Cancer Research Annual Meeting 2023.
Circle Pharma announced that two poster presentations at the American Association for Cancer Research Annual Meeting held April 14-19, in Orlando, Florida, highlight promising pre-clinical data of its first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors targeting intractable cancers.
OSE Immunotherapeutics SA presented two additional posters reporting the latest research updates on CLEC-1, from its Myeloid platform, at the 2023 American Association for Cancer Research Annual Meeting held in Orlando on April 14-19.
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce the launch of CUVRIOR to treat stable Wilson Disease in adults who are de-coppered and able to take penicillamine.
When a person notifies their employer that they have a disability, the company must make a good-faith effort to adjust to enable the employee to continue in their job.
Understanding Your Rights: A Guide to Requesting Disability Accommodations at Work Read More »
As companies prioritize in-person work, many have begun to do more to incentivize a reluctant workforce to come into the office.
Employers Raise the Stakes to Get Employees Back in Office Read More »
